Results 151 to 160 of about 1,442,988 (353)

Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies (αEpCAM × αCD3) [PDF]

open access: bronze, 2001
Rainer Riesenberg   +3 more
openalex   +1 more source

Efficient Antibody Structure Refinement Using Energy-Guided SE(3) Flow Matching [PDF]

open access: yesarXiv
Antibodies are proteins produced by the immune system that recognize and bind to specific antigens, and their 3D structures are crucial for understanding their binding mechanism and designing therapeutic interventions. The specificity of antibody-antigen binding predominantly depends on the complementarity-determining regions (CDR) within antibodies ...
arxiv  

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner   +7 more
wiley   +1 more source

Teclistamab as an Effective Treatment for Pericardial Effusion in Relapsed Multiple Myeloma: Case Report and a Brief Literature Review

open access: yesCase Reports in Oncology
Introduction: Multiple myeloma represents a malignant disorder of plasma cells. Extramedullary relapse in multiple myeloma is a rare occurrence, and pericardial involvement stands as an exceedingly uncommon manifestation.
Sai Samyuktha Bandaru   +3 more
doaj   +1 more source

Energy-based generative models for monoclonal antibodies [PDF]

open access: yesarXiv
Since the approval of the first antibody drug in 1986, a total of 162 antibodies have been approved for a wide range of therapeutic areas, including cancer, autoimmune, infectious, or cardiovascular diseases. Despite advances in biotechnology that accelerated the development of antibody drugs, the drug discovery process for this modality remains ...
arxiv  

Bispecific Monoclonal Antibodies Mediate Binding of Dengue Virus to Erythrocytes in a Monkey Model of Passive Viremia [PDF]

open access: bronze, 2001
Chang S. Hahn   +4 more
openalex   +1 more source

Furmonertinib in uncommon EGFR‐mutated non‐small cell lung cancer with central nervous system metastases: A retrospective cohort study

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Mutations in EGFR are the most frequently detected driver mutations in non‐small cell lung carcinoma (NSCLC), and two common mutations account for 75%–90% of these. The remaining 10%–25% are uncommon mutations, a heterogeneous set of genetic changes that do not necessarily respond well to treatment.
Yuwen Xie   +7 more
wiley   +1 more source

Leveraging Large Language Models to Predict Antibody Biological Activity Against Influenza A Hemagglutinin [PDF]

open access: yesarXiv
Monoclonal antibodies (mAbs) represent one of the most prevalent FDA-approved modalities for treating autoimmune diseases, infectious diseases, and cancers. However, discovery and development of therapeutic antibodies remains a time-consuming and expensive process. Recent advancements in machine learning (ML) and artificial intelligence (AI) have shown
arxiv  

Home - About - Disclaimer - Privacy